April 15, 2024 07:19 AM EDTUpdated 10:33 AM
R&D

FDA hits Neumo­ra with clin­i­cal hold for schiz­o­phre­nia drug af­ter pre­clin­i­cal da­ta showed con­vul­sions in rab­bits

Katherine Lewin

News Reporter

Neumo­ra Ther­a­peu­tics has hit a road block to be­com­ing a ma­jor neu­ro­science play­er, with the FDA plac­ing a clin­i­cal hold on a Phase 1 study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times